Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cytek Biosciences Inc (CTKB)

Cytek Biosciences Inc (CTKB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Cytek Biosciences to participate at the TD Cowen 46th Annual Health Care Conference

FREMONT, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming...

CTKB : 4.43 (+2.07%)
Cytek Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

FREMONT, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the fourth quarter...

CTKB : 4.43 (+2.07%)
Cytek Biosciences Announces Preliminary Fourth Quarter and Full Year 2025 Revenue Results

FREMONT, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced preliminary, unaudited revenue results for the fourth...

CTKB : 4.43 (+2.07%)
TIME Recognizes Cytek® Biosciences as One of America’s Growth Leaders of 2026

FREMONT, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Spectral flow cytometry leader  Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced its inclusion on TIME’s 2026 list of America’s Growth Leaders....

CTKB : 4.43 (+2.07%)
Cytek® Muse® Micro Cell Analyzer Wins BioTech Breakthrough Award for Drug Discovery Solution of the Year

FREMONT, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB) announced today that its Cytek ® Muse ® Micro cell analyzer has been named Drug Discovery Solution...

CTKB : 4.43 (+2.07%)
Cytek Biosciences to Participate in Upcoming Investor Conferences

FREMONT, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following...

CTKB : 4.43 (+2.07%)
Cytek Biosciences Reports Third Quarter 2025 Financial Results

FREMONT, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Cytek ®  Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial...

CTKB : 4.43 (+2.07%)
Cytek® Biosciences Deepens Commitment to Expanding Access to Flow Cytometry

FREMONT, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Amid the reduction of various government grant programs and global economic challenges that have tightened research funding, Cytek Biosciences, Inc....

CTKB : 4.43 (+2.07%)
Cytek Biosciences to Report Third Quarter 2025 Financial Results on November 5, 2025

FREMONT, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the third quarter...

CTKB : 4.43 (+2.07%)
Cytek® Biosciences Expands European Presence with New Facility in Amsterdam to Better Serve Customers and Drive Growth

FREMONT, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- In a move that strengthens its European operations and enhances service for its customers, spectral flow cytometry leader Cytek Biosciences, Inc. ...

CTKB : 4.43 (+2.07%)

Barchart Exclusives

Warren Buffett’s Last Investment Was This Stock. Should You Follow the Oracle and Buy It Too?
Buffett's Berkshire picked up five million shares of the newspaper company. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar